Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

To REMS Or Not To REMS? Erivedge Shows Division At FDA Over Oncology Risk Management

Nov 01 2012

• By Sue Sutter

Related Content

Oncology Has Different Risk Management Standards, FDA’s Pazdur Acknowledges

Jun 13 2011

<em>Erivedge</em> Efficacy Overcomes Limitations Of Single-Arm Study

Nov 01 2012

<em>Erivedge</em> Development Timeline

Nov 01 2012

<em>Erivedge</em> May Be The <em>Gleevec</em> Of Hedgehog Inhibitors

Feb 13 2012

Curis Set For Transformative Year With <em>Erivedge</em> Skin Cancer Approval

Feb 06 2012

FDA’s Decision To Back Off <em>Korlym</em> REMS Shows Context Is King

Sep 01 2012

Related Companies

Genentech, Inc.

AstraZeneca PLC

Bristol Myers Squibb Company

Curis, Inc.

Corcept Therapeutics Incorporated

Additional Topics

United States BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window